Novel drug delivery technologies for value-added medicines5 Mar 2018
Licensing agreement enables Recipharm to co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.
Recipharm has signed a licensing agreement with Altus Formulation, a Canadian drug development company, to allow its customers to access new drug delivery technologies and products.
Under the terms of the agreement, Recipharm will co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.
Intellitab is a novel misuse and abuse-deterrent technology that mitigates the dangers of over-exposure to opioids that can occur due to inadvertent or deliberate tampering with immediate release or extended release narcotics. Intellitab tablets are hardened to resist cutting, crushing and chewing, common methods to accelerate drug release, and spontaneously form hard, stable gels in a range of solvents to deter injection. To date, the technology has been used for the development of both narcotic and stimulant products for sale in North America.
Flexitab is a commercially validated extended-release technology enabling alcohol resistant tablets that maintain their performance after breaking to generate bio-equivalent lower strength tablets. As a result, Flexitab tablets may be broken with no risk of dose dumping or loss of controlled release, eliminating the need for multiple tablets for patients whose regime requires the ability to titrate to effect. The technology can be used to generate novel enhanced generic tablets and to increase the value of existing non-breakable extended-release products.
”This collaboration is an exciting step for Recipharm, enabling us to bring innovative drug delivery technologies to our customers and ultimately develop novel, safer and cost-effective new products. We look forward to working with Altus to increase the use of its technologies in Europe”, says Bernard Pluta, President Development Services at Recipharm.
”We are delighted to enter into this agreement and look forward to co-developing a range of patent protected, label differentiated new products with Recipharm and its customers”, says Damon Smith, CEO of Altus.
New gene therapy manufacturing facility for Orchard Therapeutics
13 Dec 2018
Enhances company's capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale.Read more
WuXi AppTec expands site in California for pharmaceutical R&D services
13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.Read more
Cambrex expands analytical capabilities
12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.Read more
Future-oriented packaging concepts from Sanner
11 Dec 2018
Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
SGS to expand bioanalytical testing capabilities
10 Dec 2018
The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.Read more
MIT engineers repurpose wasp venom as an antibiotic drug
9 Dec 2018
Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.Read more
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases
5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation